No consensus has been reached on the optimal salvage regimen for relapsed metastatic germ cell cancer. We sought to improve the efficacy of the TIP (paclitaxel, ifosfamide, cisplatin) regimen by adding Gem (gemcitabine). This had no detrimental effect on the dose intensity of TIP. The overall complete response rate was 50%, with 1-year failure-free survival of 68%. Gem-TIP is therefore a novel and viable regimen in this setting. Background: Metastatic germ cell tumors remain potentially curable when treated with salvage chemotherapy at first relapse. In the present phase I/II study, we sought to improve on the response rate and duration of the TIP (paclitaxel, ifosfamide, cisplatin) regimen by adding gemcitabine (Gem-TIP). Materials and Methods: Twenty patients were recruited after failure of first-line cisplatin-containing chemotherapy. The primary objectives were to determine the maximum tolerated dose of gemcitabine when combined with TIP and to establish the dose intensity of the TIP drugs in this combination. The secondary objectives were the response rates, failure-free survival, and overall survival. Results: The maximum tolerated dose of gemcitabine was 1200 mg/m 2 . The mean relative dose intensity was 95%
Introduction
Germ cell cancer of the testis (GCT) is the most common malignancy diagnosed in men aged 15 to 40 years in developed countries, with an age-standardized incidence of 6.7 per 100,000 men in Northern Europe. 1 Most patients with metastatic disease will be cured with first-line cisplatin-based combination chemotherapy. The outcome for the 15% to 20% who experience disease relapse after first-line therapy is less certain, although a substantial number will be cured with salvage treatment. 2 study, TIP produced a response rate of 60%, with 1-year progressionfree survival and overall survival (OS) rates of 38% and 70%, respectively. 5 Using a more intensive regimen with growth factor support, the Memorial Sloan Kettering Cancer Center (MSKCC) achieved greater response rates, albeit in a good prognosis cohort. 4 TIP has consequently become one of the most widely used salvage regimens. Efforts have been made to improve on these data using highdose and sequential therapies with stem cell rescue. However, no consensus has been reached regarding the optimal treatment in this setting.
Gemcitabine has documented clinical activity in germ cell cancer as a single agent 6, 7 or in combination. [8] [9] [10] It has been combined with cisplatin and ifosfamide, with a 2-year OS rate of 73% in the relapsed setting. 11 We sought to improve on the efficacy of TIP by adding gemcitabine to the regimen (Gem-TIP), with the aim of developing a tolerable, highly active, salvage chemotherapy regimen to be used in patients with metastatic germ cell cancer for whom first-line chemotherapy have failed.
Materials and Methods

Study Design and Treatment
The Gem-TIP trial was a nonrandomized, open-label, multicenter single-arm phase I/II study. The dose of intravenous (IV) gemcitabine was escalated within the phase I trial to determine the maximum tolerated dose (MTD) in combination with the other 3 drugs. A 3þ3 design was used, with 3 dose levels investigated: 600 mg/m mg/m 2 IV on days 1 to 5, ifosfamide 1 g/m 2 IV on days 2 to 6, with peg-filgrastim 6 mg subcutaneously on day 7 of a planned 21-day cycle (maximum of 4 cycles). Subsequent cycles were started at the achievement of adequate hematologic recovery (unsupported neutrophils > 0.5 Â 10 9 /L and platelets > 100 Â 10 9 /L) with no planned dose reductions. The patients received a maximum of 4 cycles.
The local research ethics committee approved the study, which was authorized by the Medicines and Healthcare Products Regulatory Agency. It was conducted in accordance with the Declaration of Helsinki principals and Good Clinical Practice guidelines. All patients provided written informed consent. The trial was registered with ClinicalTrials.gov (Clinicaltrials.gov identifier, NCT00551122) and the ISRCTN registry (ISRCTN no. ISRCTN37453564).
Patients
Patients were eligible if aged 16 to 60 years, with a first relapse of metastatic GCT, after failure of treatment with first-line cisplatincontaining combination chemotherapy. Patients were required to have had increasing serum tumor marker (alpha-fetoprotein, b-human chorionic gonadotropin) levels on sequential measurement, or biopsy proven unresectable GCT. The laboratory criteria included a white blood cell count > 3.5 Â 10 9 /L, platelet count > 130 Â 10 9 /L, and glomerular filtration rate ! 50 mL/min. Patients were ineligible if they were not fit enough to receive Gem-TIP or if they had primary intracranial tumors, completely resected disease, isolated cerebral metastases, or a previous malignancy (excluding nonmelanomatous skin cancer or superficial bladder cancer).
Evaluation and Outcomes
Clinical assessments and tumor marker evaluations were performed monthly for 4 months and then every 2 months until 12 months after treatment. A full blood count was performed twice weekly during chemotherapy. Toxicity was graded using the Common Terminology Criteria for Adverse Events, version 3.0. Chest radiography and computed tomography (CT) of the head, chest, abdomen, and pelvis were performed at baseline, with an additional chest radiograph performed before each cycle. CT of the chest, abdomen, and pelvis (the head was included if clinically indicated) was performed 3 weeks after the final cycle. For those patients without a complete response (CR), surgery was considered for those with nonseminoma. Otherwise, CT and tumor marker evaluations were repeated 3 months later. The patients were considered to have a CR if they had both normal marker levels and normal CT findings, either after chemotherapy alone or after chemotherapy with complete resection of teratoma differentiated and/or necrotic tissue. A complete response with surgery (CRs) was allocated to those achieving a CR after resection of viable cancer but with normal postoperative markers. Patients were considered to have a partial response (PR) if they had unresectable residual masses and normal tumor marker levels. Patients had an incomplete response (IR) if they did not have a CR or PR, including those with increasing serum tumor marker levels and/or incompletely resected or progressive malignant lesions. The favorable response rate included those with a CR, CRs, or PR.
For patients with a CR, no further treatment was recommended. Those with normal tumor marker levels and positron emission tomography (PET) findings but with residual masses were evaluated for surgery. Further chemotherapy was not recommended. Those with positive PET findings but normal tumor marker levels were advised to undergo a biopsy. Chemotherapy was not advised on the basis of positive PET scan findings alone. Only those with progressive disease or with incompletely resected active malignancy were recommended for consideration of high-dose chemotherapy or alternative further treatment outside of the trial.
Statistical Analysis
The primary endpoint of the phase I trial was the MTD of gemcitabine within the regimen. Once this was reached, a further cohort of 14 patients was to be treated at this dose level. The number of additional patients was determined by the need to estimate, with reasonable accuracy, the relative dose intensity (RDI) of paclitaxel, ifosfamide, and cisplatin, when given with gemcitabine. We calculated that a minimum of 17 patients, including those from the phase I cohort, would be sufficient to ensure that the lower 95% CI for the estimated RDI would be no more than 4% less than the mean.
The primary endpoint of the phase II trial was the RDI of paclitaxel, ifosfamide, and cisplatin (calculated as the percentage of the actual dose intensity relative to the planned dose intensity). The secondary endpoints included the RDI of gemcitabine, response rate, failure-free survival (FFS), and OS. FFS and OS were calculated as time to event variables (from the date of initiation of chemotherapy). FFS events included IR, marker-positive relapse after PR/CR, and death from any cause. Serious adverse events and toxicity experienced 30 days after chemotherapy were the safety endpoints.
Statistical analysis was performed using SAS, version 9.3. Survival analyses were summarized using Kaplan-Meier curves. The primary population consisted of all evaluable patients, which included all eligible phase I/II patients but excluded those who had withdrawn because of a nontreatment-related event during chemotherapy, as agreed by the data monitoring and ethics committee. The safety analyses included data from all eligible patients.
Results
Patient Characteristics
At completion of the phase I study, 6 patients had received the MTD of 1200 mg/m 2 of gemcitabine and were deemed evaluable.
The patient who was registered but excluded from the analysis had required a change in the treatment plan after additional imaging (requiring high-dose chemotherapy), before beginning Gem-TIP. Sixteen patients were registered for the phase II trial from March 2010 to August 2012 at a total of 5 centers. Two of these patients were deemed nonevaluable because of noncompliance during the treatment phase for reasons unrelated to the treatment. Therefore, the 6 patients from the phase I stage and 14 patients from the phase
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Salvage Chemotherapy With Gem-TIP II stage were combined, for a total evaluable sample size of 20 (the consort diagram is shown in Figure 1 ). The patient characteristics are summarized in Table 1 . Of the 20 participants, 19 were men, with a median age of 32.5 years (range, 20-61 years). The most common site of relapse was abdominal (55%). Using the International Prognostic Factors Study Group score, 12 8 patients were considered low risk, 6, intermediate risk, and 5, high risk (the female patient was excluded because this score is not applicable; Table 1 ).
Treatment
Of the 20 evaluable patients who began treatment with Gem-TIP, 17 received all 4 cycles of chemotherapy (85%). Treatment was stopped during cycle 4 for 1 patient who had become unwell with symptoms of an upper respiratory tract infection and later declined to restart treatment. Treatment was stopped for 1 patient after cycle 3 because of neuropathy and for 1 patient during cycle one because of pulmonary toxicity. The median time between cycles was 21 days (range, 19-30 days). The mean RDI was 95% (95% CI, 90.2%-99.2%) for gemcitabine, 96% (95% CI, 92.9%-98.7%) for paclitaxel, 92% (95% CI, 89.5%-98.8%) for ifosfamide, and 94% (95% CI, 89.3%-99.0%) for cisplatin (Supplemental Table 1 ; available in the online version). The proportion of patients receiving > 85% RDI for each drug was 85% for gemcitabine, 90% for Female patient excluded because cannot be scored using these criteria.
e Prognostic score using the MSKCC criteria, 4 in which a poor prognosis equals a mediastinal or retroperitoneal primary and/or an incomplete response to first-line treatment.
paclitaxel, 80% for ifosfamide, and 85% for cisplatin. Three patients required a dose reduction for gemcitabine: 2 because of thrombocytopenia and 1 because of acute renal failure.
Toxicity
No dose-limiting toxicities were seen for the 600-mg/m 2 and 900-mg/m 2 phase I cohorts, as reported previously. 13 Twenty-two serious adverse events were reported in 9 patients: 3 were life threatening (2 occurrences of thrombocytopenia in the same patient and 1 episode of respiratory failure secondary to pulmonary toxicity), with the remainder requiring hospitalization or prolongation of existing hospitalization. Grade 3/4 hematologic toxicity was observed in 18 of 23 patients (78.3%). The most common were grade 3/4 thrombocytopenia (15 of 23; 65.2%) and neutropenia (12 of 23; 52.2%). At least one platelet transfusion was given to 11 of 23 patients (47.8%) and blood transfusion to 15 of 23 (65.2%). Grade 3/4 nonhematologic toxicity was observed in 10 of 23 patients (43.5%), with the most common being sensory neuropathy, elevated creatinine, and IV line infection. Six patients experienced a septic complication requiring IV antibiotics. No toxic deaths were experienced during Gem-TIP chemotherapy. A summary of hematologic toxicities and septic complications is presented in Table 2 , with nonhematologic toxicities presented in Supplemental Table 2 (available in the online version).
Response Rates and Survival
Nine of 20 patients had a CR (45%), with an additional patient achieving a CRs, for an overall CR rate of 50% (10 of 20). Another 6 patients had a PR (30%). Therefore, the overall favorable response rate was 80% (16 of 20). Of those remaining, 3 patients (15%) had an IR and 1 (5%) was lost to follow up ( Table 3 ). The 1-year FFS rate was 68% (95% CI, 43%-84%). The median FFS was not reached, with a median follow-up time of 26 months (95% CI, 17-60 months; Figure 2A ). The 2-year FFS rate was 63.2% (95% CI, 37.9%-80.4%). For the 14 patients considered to have a good prognosis at screening, the 1-year FFS rate was 77% (95% CI, 44%-92%) and for the 6 with a poor prognosis, it was 50% (95% CI, 11%-80%; Figure 2B ). For the 15 patients with a testicular primary, the 1-year FFS rate was 79% (95% CI, 47%-93%). Overall, 7 FFS events occurred. In addition to the 3 patients with an IR, 4 patients developed a relapse after a CR, CRs, or PR. In 3 patients, the site of relapse was not documented, was elevated tumor marker levels only, or was the brain. In the remaining patient, the sites of relapse were the abdomen and lungs.
For all 20 evaluable patients, the 1-year OS rate from beginning chemotherapy was 89.5% (95% CI, 64%-97%). The median OS was not reached, with a median follow-up of 25 months (95% CI, 18-42 months; Figure 3 ). The 1-year OS rate for the 15 patients with a testicular primary was 93% (95% CI, 59%-99%). Overall, 4 patients died (20.0%); all 4 deaths were related to germ cell cancer, and 1 patient had been in the good prognosis group. 
Salvage Chemotherapy With Gem-TIP
Further Treatment
The postprotocol treatment was at the discretion of the treating physician. Of the 7 patients who experienced disease relapse, 4 subsequently received high-dose chemotherapy with peripheral stem cell rescue (HDCT), 1 received standard dose salvage chemotherapy in addition to radiotherapy, and 2 patients underwent radiotherapy alone (to the brain only and to the brain and vertebra). Of the 4 patients receiving HDCT, 1 had died, 2 had active disease, and 1 was disease free at the last follow-up visit, with a median follow-up of 18 months. All 3 patients not treated with HDCT had died within 1 year.
Of the 13 patients without disease relapse, 3 patients received further treatment outside of the protocol. One patient received standard-dose chemotherapy, in addition to consolidation radiotherapy to the abdomen. A second patient underwent consolidation radiotherapy to the mediastinum. The third patient received 2 cycles of back-to-back HDCT, followed by a retroperitoneal lymph node dissection, which revealed teratoma, differentiated. Consolidation with high-dose therapy in the absence of high-grade residual disease/relapse was not recommended; it was, however, standard practice in some institutions.
Discussion
The optimal treatment regimen for patients in first relapse of metastatic germ cell cancer has not yet been determined. We sought to intensify the established MRC TIP regimen 5 with the addition of gemcitabine. Most patients received > 85% RDI for each drug, improving on the dose intensity previously achieved, 5 perhaps in part because of We have shown Gem-TIP to have high activity as a second-line treatment for metastatic germ cell cancer, with an overall CR rate of 50% and a 1-year FFS rate of 68%. These response rates compare favorably with those from the MRC TIP trial 5 and are broadly comparable to those reported from the MSKCC TIP trial, which produced a 2-year progression-free survival of 65%. 4 However, all the patients enrolled in the MSKCC trial had favorable prognostic features, but 30% of the patients enrolled in the present study were in the poor prognosis category. Higher doses of paclitaxel and ifosfamide were used in the MSKCC regimen; we instead sought to assess the feasibility and safety of adding a fourth agent to the regimen. The 3 patients without documented disease relapse were given further treatment outside of the protocol recommendation. One received 2 autologous stem cell transplantations after high-dose chemotherapy. This treatment, beyond what was deemed necessary within the trial, could have had a beneficial effect on the apparent efficacy of Gem-TIP.
The most common toxicity was hematologic and moderately severe (grade 3/4 in 78.3% of the patients). Neutropenia was less pronounced with Gem-TIP compared with TIP, probably secondary to the routine use of growth factors in the present study. However, thrombocytopenia was predictably more pronounced with the addition of gemcitabine. Only 2 patients required a dose reduction for this reason; however 1 patient experienced a grade 3/4 per rectum bleeding event related to a low platelet count. No patient died of toxicity. Although not insignificant, the toxicity of this regimen was manageable.
In the relapsed setting, metastatic GCTs remain potentially curable. How this is best achieved remains under debate. A randomized phase III trial, TIGER (EORTC 1407), has begun, to prospectively assess HDCT versus conventional chemotherapy as first salvage treatment.
14 Data on the long-term morbidity after HDCT are lacking. Given the median age of 32 years in 1 large retrospective analysis, 15 it is clearly important to consider which patients need to receive HDCT intensification to spare those who do not from unnecessary toxicity.
Conclusion
We have established that gemcitabine can be safely added to full-dose MRC TIP chemotherapy with manageable toxicity and no detrimental effect on the relative dose intensity of the TIP drugs. The likelihood of evaluating the efficacy of Gem-TIP in a larger randomized setting will depend on the outcomes of the TIGER trial.
Clinical Practice Points
No consensus has been reached on the optimum salvage regimen for patients with metastatic GCT at first relapse. TIP is one of the most widely used, with 1-and 2-year progression-free survival rates of 38% and 65% previously reported. 4, 5 By adding gemcitabine to the TIP regimen, we sought to improve its efficacy without compromising safety.
To the best of our knowledge, no studies of this regimen for relapsed GCT have been previously reported. In combination with the TIP drugs, the maximum tolerated dose of gemcitabine was 1200 mg/m 2 . No detrimental effect on the dose intensity of the TIP drugs was found. The overall CR rate was 50%, with 1-year FFS and OS rates of 68% (95% CI, 43%-84%) and 89.5% (95% CI, 64%-97%), respectively. Hematologic toxicity was moderately severe but manageable, with grade 3/4 toxicity in 78.3% of patients, but no deaths from toxicity. Thus, we have established that gemcitabine can safely be added to full-dose TIP chemotherapy. The present trial presents a novel and viable regimen for the treatment of relapsed metastatic GCT. The likelihood of evaluating the efficacy of Gem-TIP in a larger randomized setting will depend on the outcomes of the TIGER trial.
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